Platelet activation and myocardial necrosis in patients undergoing radiofrequency and cryoablation of isthmus-dependent atrial flutter.
OBJECTIVE
Lower platelet activation by cryoenergy compared with radiofrequency (RF) energy was recently demonstrated immediately following ablation procedures of cardiac arrhythmias. Due to the delayed occurrence of cryolesions it is currently unknown, if cryoenergy and RF energy are associated with similar platelet activation and myocardial necrosis in the days after the procedure.


RESULTS
We enrolled 38 patients with common atrial flutter undergoing cavotricuspid isthmus ablation with either RF energy (n = 23) or cryoenergy (n = 13). Ten patients undergoing RF ablation and receiving aspirin served as antiplatelet control group. Troponin T and platelet surface protein expression of P-selectin were determined before and immediately after ablation as well as on day 1 and 2 thereafter. Rise in troponin T was amplified after RF ablation (0.50 +/- 0.37 microg/L) when compared with cryoablation (0.24 +/- 0.20 microg/L; P = 0.024). In patients without aspirin, a significant increase in P-selectin expression was observed on day 1 after intervention in RF ablation compared with cryoablation (80 +/- 26 vs. 63 +/- 16 arbitrary units; P = 0.048). Platelet activation was attenuated in patients receiving aspirin.


CONCLUSIONS
Successful ablation of atrial flutter with cryoenergy is associated with less myocardial necrosis and platelet activation compared with ablation with RF energy. Increased platelet activation following RF ablation can be attenuated by concomitant treatment with aspirin.
Hochholzer
Willibald
W
Herz-Zentrum Bad Krozingen, Suedring 15, 79189, Bad Krozingen, Germany. willibald.hochholzer@herzzentrum.de
Schlittenhardt
Daniel
D
Arentz
Thomas
T
Stockinger
Jochem
J
Weber
Reinhold
R
Bürkle
Gerd
G
Kalusche
Dietrich
D
Trenk
Dietmar
D
Neumann
Franz-Josef
FJ
D000925:Anticoagulants / Q000008:administration & dosage; D001241:Aspirin / Q000008:administration & dosage; D001282:Atrial Flutter / Q000601:surgery*; D015415:Biomarkers / Q000097:blood; D017115:Catheter Ablation / Q000009:adverse effects*; D016009:Chi-Square Distribution; D003452:Cryosurgery; D005260:Female; D005434:Flow Cytometry; D006801:Humans; D008297:Male; D008875:Middle Aged; D009336:Necrosis; D019007:P-Selectin / Q000097:blood; D015539:Platelet Activation; D010979:Platelet Function Tests; D040201:Platelet Membrane Glycoprotein IIb / Q000097:blood; D018709:Statistics, Nonparametric; D016896:Treatment Outcome; D020107:Troponin T / Q000097:blood
D000925:Anticoagulants; D015415:Biomarkers; D019007:P-Selectin; D040201:Platelet Membrane Glycoprotein IIb; D020107:Troponin T; D001241:Aspirin